Related Experiment Video
Updated: Nov 1, 2025

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
Blood pressure control in patients with chronic kidney disease
Jee Young Lee1, Seung Hyeok Han1
1Department of Internal Medicine, Institute of Kidney Disease Research, Yonsei University College of Medicine, Seoul, Korea.
Insights
Achieving optimal blood pressure (BP) control is crucial for patients with chronic kidney disease (CKD). While lower BP targets reduce cardiovascular events, the optimal BP goal for CKD patients remains debated, especially for advanced stages.
Area of Science:
- Nephrology
- Cardiology
- Hypertension Management
Background:
- Uncontrolled blood pressure (BP) in chronic kidney disease (CKD) patients elevates risks of cardiovascular events (CVEs) and end-stage kidney disease.
- The Systolic Blood Pressure Intervention Trial (SPRINT) influenced a paradigm shift towards lower systolic BP (SBP) targets, now recommended by KDIGO 2021 guidelines.
- Controversy exists regarding intensive SBP control (< 120 mmHg) in CKD patients, with potential risks to kidney outcomes.
Purpose of the Study:
- To review the optimal BP control strategies for CKD patients.
- To evaluate the benefits of BP management in reducing mortality and CVEs.
- To assess the impact of BP control on attenuating CKD progression.
Main Methods:
- Literature review of evidence-based studies on BP management in CKD.
- Analysis of randomized controlled trials and observational data.
- Discussion of SPRINT and KDIGO guidelines in the context of CKD.
Main Results:
- Lower SBP targets (< 120 mmHg) show potential for reducing CVEs in the general population.
- The efficacy and safety of intensive SBP control (< 120 mmHg) specifically in CKD patients, particularly advanced CKD, require further investigation.
- Current evidence is limited by a lack of dedicated randomized controlled trials in CKD populations.
Conclusions:
- Optimal BP control is essential for managing CKD complications, including CVEs and CKD progression.
- While lower SBP targets are beneficial, the specific target for CKD patients needs careful consideration due to potential adverse kidney outcomes.
- Further research, especially RCTs in CKD populations, is needed to establish definitive BP targets.
Abstract:
Uncontrolled blood pressure (BP) in patients with chronic kidney disease (CKD) can lead to serious adverse outcomes. To prevent the occurrence of cardiovascular events (CVEs), and end-stage kidney disease, achieving an optimal BP level is important. Recently, there has been a paradigm shift in the management of BP largely as a result of the Systolic Blood Pressure Intervention Trial (SPRINT), which showed a reduction in CVEs by lowering systolic BP to 120 mmHg. A lower systolic blood pressure (SBP) target has been accepted by the Kidney Disease: Improving Global Outcomes (KDIGO) 2021 guidelines. However, whether intensive control of SBP targeting < 120 mmHg is also effective in patients with CKD is controversial. Notably, this lower target SBP is associated with a higher risk of adverse kidney outcomes. Unfortunately, there have been no randomized controlled trials on this issue involving only patients with CKD, particularly those with advanced CKD. In this review, we discuss the optimal control of BP in patients with CKD in terms of reduction in death and CVEs as well as attenuation of CKD progression based on the evidence-based literature.
Related Concept Videos
Hypertension and Regulation of Blood Pressure
Blood Pressure
The average BP in an adult is typically around 120/80 mmHg (millimeters of mercury). In this measurement, the numerator (120) indicates the systolic pressure, which is the pressure in the arteries during the contraction of the heart's ventricles as blood is expelled. The denominator (80) represents the...
Blood Pressure
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction

